55 results about "Desoxycholic acid" patented technology

The invention discloses a kit for testing 3-sulfate glycochenodeoxycholic acids and glycochenodeoxycholic acids in blood, which consists of internal standard isoleucine peptides, buffer solution ammonium acetates and acetonitrile. A method for testing the 3-sulfate glycochenodeoxycholic acids and glycochenodeoxycholic acids in blood by using the kit has the characteristics of low testing cost, good repeatability, high stability, speediness, and high efficiency; and a test on an actual sample by the kit only takes19 minutes, therefore, the kit is suitable for clinical application.

The invention discloses a preparation method of a novel amphiphilic polymer of deoxycholate-modified chitosan oligosaccharide. The preparation method is applied to the encapsulation of oleanolic acid,aims at improving the bioavailability and stability of the oleanolic acid, and comprises the following steps that 1, firstly, chitosan oligosaccharide and a deoxycholate solution are formed in an organic solvent; 2, the deoxycholate is grafted to the chitosan oligosaccharide to obtain the amphiphilic polymer of the deoxycholate-modified chitosan oligosaccharide; 3, the amphiphilic polymer is added into an organic solvent to form a deoxycholate-modified chitosan oligosaccharide dispersion solution; 4, an oleanolic acid solution is dropped into the deoxycholate-modified chitosan oligosaccharidesolution to form deoxycholate-chitosan oligosaccharide encapsulated oleanolic acid nanoparticles through self-assembly. The maximum encapsulation rate and drug loading rate of the obtained nanoparticles are 80.50% and 53.61% respectively, the particle diameter is 250 +/- 25 nanometers, the bioavailability of the oleanolic acid is significantly improved, the application of the physiological functions of the oleanolic acid in the medical field is enhanced, and a novel material is provided for an oral delivery system of hydrophobic drugs.

The invention provides a use of a combined serum metabolic marker in the preparation of a kit for diagnosing the progress of hepatopathy, the kit, and a method using the kit to screen serum metabolicmarkers, and relates to the technical field of serum metabolic markers. The combined serum metabolic marker is mainly composed of sodium glycochenodeoxycholate sulfate, glycochenodeoxycholic acid, glycodesoxycholic acid, glycocholic acid and taurochenodeoxycholic acid. The kit executes combined screening detection on the content of above serum metabolites in serum in order to realize assisted diagnosis of the progress of the hepatopathy of hepatopathy patients, so the difficult monitoring problem of the occurrence and development of the hepatopathy in existing clinic therapy of the hepatopathyis effectively alleviated.

The invention provides a levofloxacin lactate liposome sodium chloride injection and a preparation method thereof. The levofloxacin lactate liposome sodium chloride injection is characterized by beingprepared with the following components according to parts by weight: 1 part of levofloxacin lactate, 5-15 parts of phospholipid, 0.5-1.5 parts of cholesterol, 0.5-2 parts of deoxycholate, 2-10 partsof sodium chloride and 0.5-1.5 parts of antioxidant. The invention adopts specific auxiliary materials to proportion with the original auxiliary materials and adopts the reverse phase evaporation method to prepare the levofloxacin lactate liposome sodium chloride injection of the invention, solving problems of unqualified levofloxacin lactate injection clarity and insoluble particles, and yellowing of solution color in the prior art. The invention provides a stable levofloxacin lactate liposome sodium chloride injection featuring long-time laying aside.

The invention provides a preparation method of an oleanolic acid slow-releasednano-microcapsule. The aim is to design and optimize oleanolic acid (OA) nanoparticles with poor water solubility to improve the oral bioavailability of the oleanolic acid (OA) nanoparticles and prolong the duration of the treatment drug level. Nanoparticle wall material is an amphiphilic polymer formed by hydrophilic chitosan oligosaccharide and hydrophobic deoxycholic acid. The particle size of nanoparticles with different wall materials is 200-400nm, and distribution is uniform. Releasing in vitro experiment is conducted in simulated gastrointestinal tract environment, results show that the oleanolic acid nanocapsule is released slowly in the simulated gastric juice and gradually released in the intestinal juice; explosive releasing is showed in early stage of releasing in the PBS solution, and then releasing is slowly; and the oleanolic acid nanocapsule is released significantly in each solution. The oleanolic acid controlled-release nanocapsule improves the bioavailability of oleanolic acid, has obvious in vitro controlled-release effect, and can be used as an effective oral preparation for future liver injury treatment.

The Qingkailing preparation for great transfusion is prepared with cholic acid 1.2-2.0 weight portions, hyodeoxycholic acid 1.4-2.4 weight portions, buffalo horn 9-16 weight portions, baicalin 1.8-3.2 weight portions, nacre 18-32 weight portions, cape jasmine 9-16 weight portions, isatis root 75-125 weight portions, and honeysuckle 23-38 weight portions. It is prepared through extraction, hydrolysis, mixing, filtering, active carbon treatment, sterilizing and other steps. The Qingkailing preparation for great transfusion has high clarity, high stability, high safety and other advantages, and is suitable for medical care personnel to use.

The invention discloses a kit for detecting 15 bile acids in serum and an application of the kit, and belongs to the technical field of blood detection. The 15 bile acids comprise a cholic acid, a glycocholic acid, a taurocholic acid, a lithocholic acid, a glycolithocholic acid, a taurolithocholic acid, a deoxycholic acid, a glycodeoxycholic acid, a taurodeoxycholic acid, a chenodeoxycholic acid,a glycochenodeoxycholic acid, a taurochenodeoxycholic acid, an ursodeoxycholic acid, a glycoursodeoxycholic acid and a tauroursodeoxycholic acid. The kit comprises an eluent, a calibration product solution, a mixed internal standard working solution, a protein precipitant and a quality control product. When the kit is used for detecting the bile acids in the serum, a to-be-detected sample does notneed derivatization treatment, pretreatment is simple, a sample dosage is small, sensitivity is high, specificity is strong, more types can be detected, the 15 types of bile acid can be simultaneously detected within 6.5 minutes, and the kit can be used for clinical diagnosis and health assessment of serum bile acids.

The invention relates to a preparation method and application of an autonomous nano generator pharmaceutical composition based on probiotic spores, can effectively solve the problems that a drug is easy to degrade in the stomach after being orally taken and the dilemma that the drug is easy to take and difficult to transport in oral administration at present, and provides construction of an oral administration system. The method comprises the following steps: firstly culturing Bacillus coagulans to generate spores, then modifying deoxycholic acid which can be combined with a bile acid receptoron the spore surfaces through amidation reaction, and then physically loading anti-tumor drugs adriamycin and sorafenib to obtain the autonomous nano generator pharmaceutical composition based on theprobiotic spores. The composition has the advantages of simple preparation method, low production cost, stable gastric acid environment and the like, retains the regeneration capacity of the drug-loaded spores, integrates a biological carrier and chemotherapy, further efficiently delivers the drugs to systemic circulation, and provides technical support for tumor treatment of oral administration.

A tacrolimus capsule is disclosed. Tacrolimus, hydroxypropyl-beta-cyclodextrin and deoxycholic acid are dissolved into absolute ethanol, then the obtained solution is granulated on pharmaceutically acceptable auxiliary materials and dried, and a capsule is filled. Compared with the prior art, the preparing process is simple, medicine dispersion is uniform, a production procedure is smooth and medicine digestion is rapid.

The invention discloses a preparation method and application of a deoxycholic-acid-modified silver nanoparticle solution. The preparation method of the deoxycholic-acid-modified silver nanoparticle solution comprises the following steps: step 1, preparing a deoxycholic acid solution; step 2, adding AgNO3 into 90 parts by weight of water to form an AgNO3 aqueous solution with a concentration of 5*10<-5>-5*10<-3> mol/L; and step 3, adding 0.005-0.012 part by weight of NaBH4 into the AgNO3 aqueous solution while performing stirring, performing continuous stirring for 1-5 min, adding 4.5-9 parts by weight of the deoxycholic acid solution, and performing continuous stirring for 0.5-5 h to obtain the deoxycholic-acid-modified silver nanoparticle solution. The prepared deoxycholic-acid-modified silver nanoparticle solution has good monodispersion, uniform particles, stable properties, and excellent optical performance.

The invention relates to the technical field of organic synthesis, in particular to a refining method of glycochenodeoxycholic acid sodium. The method includes the steps of S1, adding commercially-available glycochenodeoxycholic acid sodium to water, adjusting the pH value into the weak acid range with an acid water solution, conducting extracting through an organic solvent, adjusting the pH valueof the water phase into the strong acid range with the acid water solution, and conducting filtering to obtain glycochenodeoxycholic acid; S2, heating and stirring the glycochenodeoxycholic acid andorganic alkali in a solvent to form salt, and conducting cooling and filtering to obtain glycochenodeoxycholic acid organic alkali salt; S3, adjusting the pH value of the glycochenodeoxycholic acid organic alkali salt in the solvent into the strong acid range with an acid water solution, and conducting filtering, washing and drying to obtain a glycochenodeoxycholic acid refined product. The methodhas the advantages of being simple and easy to operate, stable in process, easy to control, beneficial for post-treatment, safe, friendly to the environment and the like, and can be continuously produced on a large scale.

The invention provides application of a mutagenic strain of which the preservation number is CCTCC (China Center For Type Culture Collection) NO: M 2020987 in preparation of deoxycholic acid. The invention provides a novel method for preparing deoxycholic acid by taking phytosterol as a raw material and combining biological fermentation and chemical synthesis, animal source extraction is not used in the method, industrial wastewater and waste residues can be used as raw materials, and the method is green and environment-friendly; the carbonyl side chain of the cholic acid compound is constructed on the side chain of the phytosterol in one step by virtue of a mycobacterium sp.NRRL B-3805 mutagenic strain biological fermentation method, so that the operation is simple, the yield is high, isomer impurities are few, and the use amount of an organic solvent is small; according to the method for preparing the deoxycholic acid compound, reaction reagents are simple and easy to obtain, reaction conditions are mild, the reaction yield is high, and the method is suitable for large-scale industrial production.

Disclosed are the general structural formula of LQC-Y as well as the synthesis and use thereof. Pharmacological experiments demonstrated the marked antitumor effect of such compounds. Single day administration of LQC-Y3 to mice at a maximum dose of 6000 mg/kg showed no toxicity response during the 14-day continuous observation period, indicating the high safety of the compounds, and the compounds can be used to prepare medicaments for preventing and treating carcinomas such as liver cancer, lung cancer. In the general structural formula of LQC-Y, R represents steroid compounds such as cholic acid, deoxycholic acid, ursodeoxycholic acid, chenodeoxycholic acid, and hyodeoxycholic acid and so on; triterpenoid compounds such as oleanolic acid, ursolic acid, pachymic acid, glycyrrhetinic acid and glycosides thereof and so on; emodic acid, emodin and other mono-substituted or poly-substituted structures of anthraquinone parent nucleus; baicalein, baicalin and other flavonoid; shikimic acid, mono-substituted shikimic acid or poly-substituted shikimic acid; gardenia acid and other iridoid acid derivatives; paeonol, curcumin and structural derivatives thereof.

The present invention discloses method for preparing deoxycholic acid (DCA) or an ester thereof or a pharmaceutically acceptable salt thereof. Said compounds may be applied to remove a fat deposition.

The present invention relates to a composition for subcutaneous injection, containing deoxycholic acid, and a preparation method therefor. The present invention relates to a composition for non-surgical removal of localized fat deposits, the composition being micro-particles, which comprise deoxycholic acid and a biodegradable polymer, wherein the microparticles are formed such that deoxycholic acid is evenly distributed in a spherical biodegradable polymer. According to the present invention, a lipolysis effect lasts for 1 to 3 months from a single injection, a phenomenon in which surrounding tissues are destroyed during administration is prevented, and a drug release effect can be maintained at an effective amount of adipolysis concentration.

Described is a chemical-enzymatic process for the preparation of ursodeoxycholic acid (UDCA) starting from deoxycholic acid (DCA), the chemical-enzymatic process comprising the preparation of an enzyme having high 7 [beta]-hydroxylase activity for the conversion of deoxycholic acid (DCA) to bear bile acid (UCA), the conversion being the first step of the process.